Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

BACKGROUND: ROS1 tyrosine kinase inhibitors (TKIs) have showed activity and efficacy in ROS1-rearranged non-small cell lung cancer (NSCLC). In the clinical practice, besides the utilization of crizotinib, less is known about the best treatment strategies involving additional, new-generation TKIs for...

Descripción completa

Detalles Bibliográficos
Autores principales: Facchinetti, Francesco, Levy, Antonin, Ammari, Samy, Naltet, Charles, Lavaud, Pernelle, Aldea, Mihaela, Vasseur, Damien, Planchard, David, Besse, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009349/
https://www.ncbi.nlm.nih.gov/pubmed/33814929
http://dx.doi.org/10.2147/CMAR.S292730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009349/
https://www.ncbi.nlm.nih.gov/pubmed/33814929
http://dx.doi.org/10.2147/CMAR.S292730

Ejemplares similares